1 / 19

Week 7: Fibrinolysis and Thrombophilia

Secondary fibrinolysis Primary fibrinolysis Plasminogen FDP D-dimer DIC 3P test. Hypercoagulable state Thrombophilia Activated protein C resistance (APCR) Factor V Leiden Antithrombin deficiency Anticoagulant therapy. Week 7: Fibrinolysis and Thrombophilia. Fibrinolysis.

Antony
Download Presentation

Week 7: Fibrinolysis and Thrombophilia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Secondary fibrinolysis Primary fibrinolysis Plasminogen FDP D-dimer DIC 3P test Hypercoagulable state Thrombophilia Activated protein C resistance (APCR) Factor V Leiden Antithrombin deficiency Anticoagulant therapy Week 7: Fibrinolysis and Thrombophilia

  2. Fibrinolysis • Plasminogen Activators • Thrombin • Tissue plasminogen activator (t-PA) • Streptokinase • Urokinase • Kallikrein • Fibrinolysis Inhibitors • 2 antiplasmin • 2 macroglobulin

  3. Fibrin(ogen) Degradation Product • X fragment: D-E-D • Y fragment: D-E • Smallest fragments: D and E • D-dimers from fibrin degradation only (ie, 2o fibrinolysis, not 1o)

  4. Fibrin Degradation

  5. FDP Screen • Thrombo-Wellco • Anti-fibrinogen coated latex • D-dimers • Positive only with 2o fibrinolysis • Plasma protaminesulfate paracoagulation (3P) • Dissociate FM-FDP to allow FM to re-associate • Also specific to 2o fibrinolysis

  6. Triggering mechanism Trauma, injury, surgery Hemolysis AML M3 Snake venom Amniotic fluid Dead fetus Gram negative endotoxin Consumptive Low PLT Long PT/APTT Low fibrinogen FDP, D-dimer Schistocyte Treatment Remove source of Tpl Heparin to stop cascade Disseminated Intravascular Coagulation

  7. Disseminated Intravascular Coagulation

  8. DIC • Syndrome, not disease • 1:1,000 hospitalized patients, but many asymptomatic • Tx: removal of underlying cause if possible • Support with FFP, PLT, RBC, etc. • Low molecular weight heparin (LMWH)

  9. Plasminogen activation without clotting Unknown mechanism Labs similar to DIC but important differences PLT unaffected No schistocyte Long PT/APTT Low fibrinogen FDP but no D-dimer Primary Fibrinolysis

  10. Thrombophilia • Tendency to form thombi • Hereditary and acquired • Hypercoagulable state • Arterial thrombi: usually in areas of atherosclerotic plaques • Venous thrombi: thrombophlebitis, DVT, pulmonary embolism

  11. Venous Thromboembolism • Venous stasis • Activated protein C resistance, factor V Leiden • Protease inhibitor deficiency (antithrombin, protein C, protein S)

  12. Antithrombin deficiency Recurrent DVT Protein C deficiency Vitamin K dependent Inactivated Va and VIIIa Protein S deficiency Vitamin K dependent Protein C cofactor APCR Factor V Leiden Prothrombin gene mutation 20210 Hereditary Thrombophilia

  13. Acquired Thrombophilia • Antiphospholipid antibody: e.g., Lupus-anticoagulant • Malignancy • Oral contraceptives • Post-op and trauma • Myeloproliferative disorders

  14. Heparin Monitor with APTT LMWH no HIT Oral anticoagulants (e.g., Coumadin) Monitor with PT Thrombolytic agents (plasminogen activators) Streptokinase Urokinase t-PA Anti-platelet agents Aspirin Plavix IV inhibitors Direct thrombin inhibitors (e.g., hirudin - from leech saliva) Not dependent on AT-III Act on thrombin’s fibrin binding site Therapies

  15. Problems with Oral Anticoagulants • GI hemorrhage • Skin necrosis • Antidote: vitamin K

  16. Problems with Heparin • Unfractionated Heparin may cause heparin induced thrombocytopenia (HIT) due to antibody against heparin-PF4 complex • LMWH: almost exclusively against Xa, less osteoporosis, less HIT • Antidote: protamine sulfate

More Related